Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973284 | 0.69 | IL1B (0.37) | HTR2ACHRM1 | |
| SCHEMBL30870497 | 0.69 | HTR2C (0.41) | — | |
| SCHEMBL30973521 | 0.68 | HTR2A (0.36) | HTR2ACHRM1 | |
| SCHEMBL9772068 | 0.61 | CHRM1 (0.44) | CHRM1 | |
| SCHEMBL9451991 | 0.61 | CHRM2 (0.50) | — | |
| SCHEMBL9342114 | 0.61 | CHRM2 (0.50) | CHRM1 | |
| SCHEMBL2855719 | 0.60 | CHRNB2 (0.49) | HTR2ACHRM1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL10433194 | 0.60 | CHRM1 (0.51) | CHRM1CHRNB2CHRNA4 | |
| SCHEMBL25244254 | 0.60 | HTR2A (0.66) | HTR2ACHRM1CHRNB2CHRNA4 | |
| SCHEMBL25769584 | 0.59 | DYRK1A (0.45) | HTR2ACHRM1CHRNB4CHRNA3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642784-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145623-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |